Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Fluzone Clear all
Completed No phase listed Observational Results available

Evaluating Modes of Influenza Transmission Observational Study of Community Acquired Influenza

NCT01769430
View directory record Official record
Conditions
Influenza Virus Infection Transmission in Humans
Interventions
Observational Study of influenza aerosol shedding -- No Intervention
Other
Lead sponsor
University of Maryland, College Park
Other
Eligibility
10 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Sep 2, 2026, 1:10 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years

NCT00952419
View directory record Official record
Conditions
Influenza, Swine-origin A/H1N1 Influenza
Interventions
Monovalent Subvirion A/H1N1 Influenza vaccine, Normal saline solution (placebo)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 9 Years
Enrollment
474 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
20
States / cities
Miami Beach, Florida • Marietta, Georgia • Woodstock, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 2, 2026, 1:10 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6-59 Months of Age

NCT00128167
View directory record Official record
Conditions
Influenza
Interventions
Liquid CAIV-T
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
6 Months to 59 Months
Enrollment
8,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
107
States / cities
Hoover, Alabama • Tuscaloosa, Alabama • Little Rock, Arkansas + 96 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2021 · Synced Sep 2, 2026, 1:10 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Safety Study of Recombinant Influenza Vaccine for Prevention

NCT02015494
View directory record Official record
Conditions
Influenza
Interventions
VAX2012Q
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 40 Years
Enrollment
316 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
4
States / cities
Lenexa, Kansas • Rochester, New York • Mt. Pleasant, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 2, 2026, 1:10 PM EDT
Completed No phase listed Observational

Performance Evaluation of LumiraDx SARS-CoV-2, Flu A/B, and RSV Tests for COVID-19 Assessment

NCT05268939
View directory record Official record
Conditions
COVID-19, Influenza A, Influenza Type B, RSV Infection
Interventions
LumiraDx SARS-CoV-2 & Flu A/B test, LumiraDx SARS-CoV-2 & RSV test
Diagnostic Test
Lead sponsor
LumiraDx UK Limited
Industry
Eligibility
Not listed
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Cullman, Alabama • Encinitas, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 2, 2026, 1:10 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older

NCT00741039
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Prostate Cancer
Interventions
inactivated influenza vaccine and the 23- valent pneumococcal vaccine, inactivated influenza vaccine and the PPV23 vaccine (Pneumovax)
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
65 Years and older
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2015 · Synced Sep 2, 2026, 1:10 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.

NCT02914275
View directory record Official record
Conditions
Influenza, Human
Interventions
Seqirus Quadrivalent Inactivated Influenza Vaccine, Comparator Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
Seqirus
Industry
Eligibility
6 Months to 59 Months
Enrollment
2,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
39
States / cities
Birmingham, Alabama • Mobile, Alabama • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Sep 2, 2026, 1:10 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age

NCT05044195
View directory record Official record
Conditions
Influenza, Human
Interventions
aQIV, Comparator QIV
Biological
Lead sponsor
Seqirus
Industry
Eligibility
50 Years to 64 Years
Enrollment
2,044 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
12
States / cities
Mobile, Alabama • Tempe, Arizona • Atlantis, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 2, 2026, 1:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Non-invasive Biometric Monitoring in Nursing Homes to Fight COVID-19

NCT04548895
View directory record Official record
Conditions
Covid19, Community-Acquired Respiratory Tract Infection
Interventions
Observational measurement of biometric data. No change to health care provided.
Device
Lead sponsor
Health Stream Analytics, LLC
Industry
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Pasco, Washington
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 2, 2026, 1:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study of Seasonal Influenza Vaccine Against H5N1 Avian Influenza Virus

NCT01044095
View directory record Official record
Conditions
Influenza
Interventions
FluMist® live, attenuated, intranasal seasonal influenza vaccine, Fluzone® inactivated influenza virus vaccine
Biological
Lead sponsor
Armed Forces Research Institute of Medical Sciences, Thailand
Government
Eligibility
18 Years to 49 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
0
States / cities
Not listed
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Sep 2, 2026, 1:10 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Assess the Safety & Immunogenicity of Stored Inactivated Influenza H5N1 Virus Vaccine Given With & Without Stored MF59 Adjuvant

NCT02680002
View directory record Official record
Conditions
A/Vietnam/H5N1 Influenza Virus
Interventions
7.5 mcg H5N1 (stored as monobulk), 15 mcg H5N1 (stored as monobulk), 90 mcg H5N1 (stored as monobulk), 90 mcg H5N1 (stored in vials), MF59, MF59 (stored as monobulk)
Biological · Other
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 49 Years
Enrollment
422 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
6
States / cities
Atlanta, Georgia • Council Bluffs, Iowa • Lenexa, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2020 · Synced Sep 2, 2026, 1:10 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine

NCT00735475
View directory record Official record
Conditions
Influenza
Interventions
CSL Limited Influenza Virus Vaccine (Afluria®), US Licensed Influenza Virus Vaccine (Fluzone®)
Biological
Lead sponsor
Seqirus
Industry
Eligibility
65 Years and older
Enrollment
1,268 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
13
States / cities
Mountain Home, Arkansas • Boise, Idaho • Iowa City, Iowa + 10 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Sep 2, 2026, 1:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine

NCT00664417
View directory record Official record
Conditions
Influenza, Orthomyxoviridae Infections
Interventions
Monovalent subvirion H5N1 influenza vaccine, Physiological saline
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 40 Years
Enrollment
375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
6
States / cities
San Diego, California • South Miami, Florida • Springfield, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2012 · Synced Sep 2, 2026, 1:10 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults

NCT05827068
View directory record Official record
Conditions
Seasonal Influenza
Interventions
mRNA-1011.1, mRNA-1011.2, mRNA-1012.1, mRNA-1010, mRNA-1010.2, mRNA-1010.3
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years to 75 Years
Enrollment
698 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
22
States / cities
Lakewood, California • Long Beach, California • Fort Collins, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 2, 2026, 1:10 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age

NCT00345579
View directory record Official record
Conditions
Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014, ActHIB, Pediarix/Infanrix Penta
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
4,432 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
61
States / cities
Birmingham, Alabama • Benton, Arkansas • Fayetteville, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 2, 2026, 1:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Feasibility of Cocooning Immunization Strategy With Influenza Vaccine

NCT00570037
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
544 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Sep 2, 2026, 1:10 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Influenza Immunity Against Pandemic Respiratory Virus

NCT00138281
View directory record Official record
Conditions
Influenza
Interventions
FluMist, Fluzone
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2006
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Sep 2, 2026, 1:10 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

H9 Priming Study in Healthy Adults

NCT00617331
View directory record Official record
Conditions
Influenza
Interventions
Subvirion inactivated influenza A/H9N2 (G9 variant) vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 59 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2011 · Synced Sep 2, 2026, 1:10 PM EDT
Completed Phase 2 Interventional Results available

Study of an Investigational Monoclonal Antibody, VIS410, in Subjects With Uncomplicated Influenza A

NCT02989194
View directory record Official record
Conditions
Influenza
Interventions
VIS410 low dose, VIS410 high dose, Placebo
Drug
Lead sponsor
Visterra, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
11
States / cities
Huntsville, Alabama • Coral Gables, Florida • Homestead, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2022 · Synced Sep 2, 2026, 1:10 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age

NCT05501561
View directory record Official record
Conditions
Influenza, Human
Interventions
Experimental: IIV-A Investigational IIV-A administered as a single dose intramuscularly on Day 1, Experimental: aIIV-B Investigational aIIV-B administered as a single dose intramuscularly on Day 1, Experimental: aIIV-C Investigational aIIV-C administered as a single dose intramuscularly on Day 1, Active Comparator: Licensed IIV IIV administered as a single dose intramuscularly on Day 1
Biological
Lead sponsor
Seqirus
Industry
Eligibility
50 Years and older
Enrollment
1,056 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
47
States / cities
Tempe, Arizona • Huntington Beach, California • San Diego, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 2, 2026, 1:10 PM EDT
Completed Not applicable Interventional

Evaluation of the School Kids Influenza Prevention Project

NCT03307642
View directory record Official record
Conditions
Childhood Influenza Vaccination, School-located Influenza Vaccination
Interventions
Text message notification
Other
Lead sponsor
University of Rochester
Other
Eligibility
4 Years to 19 Years
Enrollment
18,540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2018 · Synced Sep 2, 2026, 1:10 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Comparison of Two Methods of Immunization for Intramuscular Injections

NCT01721083
View directory record Official record
Conditions
Consequences of Immunization Method
Interventions
Procedure: Z-track, Procedure: Bunch
Procedure
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Sep 2, 2026, 1:10 PM EDT
Completed No phase listed Observational

Respiratory Virus Outpatient Study (FLU 002 Plus)

NCT01056354
View directory record Official record
Conditions
Influenza and Other Novel Respiratory Viruses
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
11,719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
17
States / cities
San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 2, 2026, 1:10 PM EDT